Clinical Trial Update: A Study to Determine Acute (After First Dose) and Chronic (After 28 Days) Effects of Empagliflozin (BI 10773) on Pre and Postprandial Glucose Homeostasis in Patients With Impaired Glucose Tolerance and Type 2 Diabetes Mellitus and Healthy Subjects [Phase 2]

View source ↗

Summary

A Phase 2 trial update reporting the acute (after first dose) and chronic (after 28 days) effects of empagliflozin on pre- and postprandial glucose homeostasis …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Impaired Glucose Tolerance
• Type 2 Diabetes Mellitus

Drugs mentioned

• Empagliflozin (empagliflozin)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Diabetes Mellitus, Type 2 | Phase 2 | Status: COMPLETED | Results posted: 2014-09-09